RBC Capital Maintains Outperform on Agios Pharmaceuticals, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) but lowered the price target from $43 to $42.

February 16, 2024 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Agios Pharmaceuticals but lowers the price target from $43 to $42.
The adjustment in price target by a prominent analyst like Gregory Renza could have a neutral to slightly negative short-term impact on AGIO's stock price. While the maintenance of an Outperform rating indicates a positive outlook on the company, the reduction in the price target might lead to mixed reactions among investors, potentially causing minor fluctuations in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100